F-1/A: Altamira Therapeutics Seeks Up to $5 Million in Public Offering to Advance RNA Delivery Platforms

Altamira Therapeutics is offering up to 5,952,380 common shares, pre-funded warrants, and associated warrants in a public offering to fund working capital and general corporate purposes.

Summary

• Altamira Therapeutics is conducting a public offering of up to 5,952,380 common shares, along with Series A-1 and A-2 warrants to purchase an equal number of common shares.
• The assumed combined public offering price is $0.84 per common share and accompanying warrants, based on the closing price on September 13, 2024.
• Pre-funded warrants are also being offered to purchasers who would otherwise exceed ownership limits, with the purchase price equal to the public offering price minus $0.002 and an exercise price of $0.002 per share.
• The offering includes placement agent warrants to purchase up to 386,904 common shares, equal to 6.5% of the shares sold in the offering, at an assumed exercise price of $1.05 per share.
• The company intends to use the net proceeds for working capital and general corporate purposes.
• H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering, which is expected to close on or about October 15, 2024, unless terminated earlier.
• The company estimates net proceeds of approximately $4.2 million, assuming full exercise of pre-funded warrants and no exercise of common warrants and placement agent warrants.
• The Series A-1 Warrants will expire on the earlier of the eighteen-month anniversary of the original issuance date or 60 days following the occurrence of Milestone 1.
• The Series A-2 Warrants will expire on the earlier of the five-year anniversary of the original issuance date or six months following the occurrence of Milestone 2.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative due to the company's need for capital and the risks associated with the offering, balanced by the potential for future growth in the RNA delivery space.

Positives

• The offering provides Altamira Therapeutics with additional capital to fund its working capital and general corporate purposes.
• The inclusion of pre-funded warrants allows larger investors to participate without exceeding ownership limits.
• The engagement of H.C. Wainwright & Co. as placement agent brings expertise in arranging the sale of securities.
• The company has flexibility in using the net proceeds, allowing it to adapt to changing business conditions.
• The offering includes warrants, which could provide additional capital if exercised in the future.

Negatives

• There is no guarantee that all securities offered will be sold, potentially reducing the amount of proceeds received.
• Investors purchasing securities in this offering will experience immediate and substantial dilution in the net tangible book value of their common shares.
• There is no established public trading market for the pre-funded warrants or common warrants, limiting their liquidity.
• The company has broad discretion in how it uses the net proceeds, which may not align with investor expectations.
• The company needs to raise capital in this offering to support its operations, and there is substantial doubt about its ability to continue as a going concern.

Risks

• The company may not raise the amount of capital it believes is required for its business plans.
• Investors in this offering will not receive a refund if the company does not sell an amount of securities sufficient to pursue its business goals.
• There is no required minimum number of securities that must be sold as a condition to completion of this offering.
• The company may be unable to fulfill its objectives due to a lack of interest in this offering.
• The company may need to raise additional funds to complete its short-term operations.
• The company's common shares may be involuntarily delisted from trading on The Nasdaq Capital Market if it fails to comply with the continued listing requirements.
• If the company is or becomes classified as a passive foreign investment company (PFIC), its U.S. shareholders and holders of the Common Warrants and Pre-Funded Warrant may suffer adverse tax consequences as a result.

Future Outlook

The company intends to use the net proceeds from this offering for working capital and general corporate purposes, but management has significant flexibility and discretion in the timing and application of the net proceeds.

Industry Context

The company is focusing on RNA delivery platforms, which is a growing area in the biopharmaceutical industry, with potential applications in cancer and inflammatory diseases.

Comparison to Industry Standards

• The document does not contain enough information to make a detailed comparison to industry standards.
• Without specific financial benchmarks or performance metrics, it is difficult to assess Altamira's position relative to its competitors.
• A thorough analysis would require comparing Altamira's RNA delivery technology, clinical trial results, and financial performance to those of other companies in the same space, such as Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, and Dicerna Pharmaceuticals.

Stakeholder Impact

• Shareholders will experience dilution as a result of the offering.
• Employees may be affected by the company's ability to continue as a going concern.
• Customers and suppliers may be impacted by the company's ability to fund its operations and development programs.
• Creditors may be affected by the company's financial condition and ability to repay its debts.

Next Steps

• The company will proceed with the public offering, seeking to sell the offered securities.
• The company will use the net proceeds for working capital and general corporate purposes.
• The company will need to monitor its compliance with Nasdaq continued listing requirements.
• The company will need to manage its cash flow and potentially seek additional funding in the future.

Key Dates

Keywords

public offering, common shares, warrants, pre-funded warrants, placement agent, H.C. Wainwright, RNA delivery, capital raise, Altamira Therapeutics, CYTO